Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | terminated | Phase 2 | 5 | Gachon University Gil Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01972672 | The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 70 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | terminated | Phase 2 | 1 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT01246986 | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | completed | Phase 2 | 204 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 12, 2021 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01687673 | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02658019 | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | Lynn Feun, MDOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03380130 | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC(NASIR-HCC) | completed | Phase 2 | 41 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT01935700 | Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma | completed | Phase 2 | 15 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | completed | Phase 1 / Phase 2 | 27 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 17, 2020 | clinicaltrials |
| NCT04150744 | RFA Plus Carrizumab vs Carrizumab Alone for HCC | recruiting | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT01775501 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | terminated | Phase 1 / Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02716766 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03578874 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | completed | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Feb 15, 2021source: clinicaltrials